Journal issues > Issue 8, December 2018 > Highlights in head and neck cancer

Highlights in head and neck cancer

The 2018 annual meeting of the European Society for Medical Oncology (ESMO) turned out to be a grand cru for head and neck cancer, with two abstracts in this disease entity presented during the presidential sessions of the meeting. These two presentations, one on the use of immune checkpoint inhibition in the frontline treatment of recurrent/metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (HNSCC) and one evaluating treatment de-escalation in low-risk, p16-positive oropharyngeal cancer, form the lion’s share of this report. In addition to this data were presented of clinical trials looking at the potential of durvalumab plus danvatirsen, M7824, tipifarnib and SD-101 in the treatment of R/M SCCHN.

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top